Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00813917 · ClinicalTrials.gov registry record · NA
Varenicline for the Treatment of Smokeless Tobacco
A NA study of Nicotine Dependence, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT00813917: Completed NA study of Nicotine Dependence, sponsored by Mayo Clinic.
NCT00813917 is a NA study of Nicotine Dependence that has completed, run by Mayo Clinic. The registered enrollment target is 76 participants, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00813917, a NA study of Nicotine Dependence, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
Varenicline (Chantix™, Pfizer) is a novel selective nicotinic receptor partial agonist with specificity for the α4β2 nicotine acetylcholine receptor that has demonstrated remarkable efficacy for increasing long-term tobacco abstinence rates in cigarette smokers. The novel mechanism of action of varenicline potentially circumvents the limitations of using nicotine replacement therapy or bupropion pharmacotherapy in ST users. The overall goal of this line of research is to develop effective pharmacologic treatments for ST users to increase long-term (≥ 6 months) abstinence rates. The central hypothesis of this application is that varenicline is efficacious for the treatment of ST users.
Primary Outcome
7-day point prevalence all tobacco abstinence at week 12 (end of treatment)confirmed by urine cotinine less than 50ng/ml
Conditions Studied
Interventions
- DRUG placebo
- DRUG varenicline
Study Locations (1)
Minnesota
- Nicotine Research Program - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-01 |
| Phase | NA |
What the finished NCT00813917 record still lists
NCT00813917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00813917 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00813917 about?
NCT00813917 is a clinical study titled "Varenicline for the Treatment of Smokeless Tobacco". Varenicline (Chantix™, Pfizer) is a novel selective nicotinic receptor partial agonist with specificity for the α4β2 nicotine acetylcholine receptor that has demonstrated remarkable efficacy for increasing long-term tobacco abstinence rates in cigarette smokers. The novel mechanism of action of vare...
What is the current status of trial NCT00813917?
This trial is currently completed. It is a NA study. The enrollment target is 76 participants. The study started on 2009-02. Estimated completion is 2011-01.
What conditions does trial NCT00813917 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT00813917?
The interventions under investigation include: placebo (DRUG), varenicline (DRUG).
Who is sponsoring clinical trial NCT00813917?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00813917 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00813917's enrollment target sits among peer trials
76 44th of 67 higher than 23 of 67 other Nicotine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)
RECRUITING · NA
-
NeuroControl of Nicotine Dependence
RECRUITING · NA
-
Abuse Liability and Appeal of Oral Nicotine Products
RECRUITING · NA
-
Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction
RECRUITING · NA
-
Young Adult Tobacco/Nicotine and Cannabis Co-use
RECRUITING · NA
-
Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia